Short Bowel Syndrome News and Research

RSS

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Collaboration seeks to uncover the best strategies to improve health care, lower costs

A group of health care organizations are joining forces to compile evidence on the strategies the work best to address a variety of common, and usually expensive, medical conditions. Meanwhile, the nation's new Medicare chief is hitting the road to hear ideas about improving the health care system.

17 Dec 2010

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

NPS third quarter net loss increases to $15.7 million

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the third quarter 2010.

2 Nov 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.

23 Jul 2010

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.

3 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

Nutricia North America improves its packaging with BPA-free lining for all powdered products

Nutricia North America, a manufacturer of medical foods and specialized infant formulas such as Neocate®, announced today that it has begun packaging its powdered medical foods and specialized infant formulas in cans with BPA-free lining.

18 Dec 2009

Research explains why recipients of growth hormone therapy may develop colon polyps

The use of growth hormone therapy has been linked in some people to the development of colon polyps, a possible precursor to colorectal cancer - but medical researchers have debated the extent of a cancer risk.

11 Apr 2006

Protein loss linked to colon polyp risk from growth hormone

10 Apr 2006

Launch of Zorbtive for use in the treatment of patients with short bowel syndrome

Serono, Inc., the US affiliate of Serono, announced today the launch of Zorbtive™ [somatropin (rDNA origin) for injection] for use in the treatment of patients with short bowel syndrome.

25 May 2004

First drug product for treatment of short bowel syndrome

Short bowel syndrome (SBS) is a rare and potentially life-threatening condition in which the ability of the small intestine to absorb the nutrition a person needs from food is impaired. Short bowel syndrome can occur after surgical removal of part of the intestine, due to trauma or because the intestine is diseased.

4 May 2004

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

6 Apr 2004